United Therapeutics Corporation
Last updated September 27, 2026
Organization details
- Legal name
- United Therapeutics Corporation
- Ownership
- Public
- Status
- Active
- Headquarters country
- United States
- Ticker symbol
- UTHR
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001082554
Board of directors
-
Christopher Causey · DirectorSince 2023
-
Christopher Patusky · DirectorSince 2023
-
Jan Malcolm · DirectorSince 2024
-
Judy D. Olian · DirectorSince 2023
-
Katherine J. Klein · DirectorSince 2023
-
Kevin Tracey · DirectorSince 2026
-
Linda Maxwell · DirectorSince 2023
-
Louis W. Sullivan · DirectorSince 2023
-
Martine A. Rothblatt · Director · Chairperson & CEOSince 2023
-
Nilda Mesa · DirectorSince 2023
-
Ray Kurzweil · DirectorSince 2023
-
Raymond Dwek · DirectorSince 2023
-
Richard Giltner · DirectorSince 2023
-
Tommy G. Thompson · DirectorSince 2023
-
Victor J. Dzau · DirectorSince 2026
Chief executives
Martine A. Rothblatt
· CHAIRPERSON & CEO
Dates unknown
Board connections
5 of this board's directors also sit on 8 other boards.
- via Judy D. Olian
- via Martine A. Rothblatt
- via Louis W. Sullivan
- via Tommy G. Thompson
- via Linda Maxwell
- via Judy D. Olian
- via Tommy G. Thompson
- via Tommy G. Thompson
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $863,940
- 1 purchase by 1 insider
- Sold, last 12 months
- $1,413,067,418
- 2558 sales by 12 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 24, 2026 | Martine A. Rothblatt Director, Officer (Chairperson & CEO) | Option exercise | +9,500 | $117.76 | $1,118,720 |
| Sep 24, 2026 | Martine A. Rothblatt Director, Officer (Chairperson & CEO) | Open-market sale | −640 | $469.74 | $300,631 |
| Sep 24, 2026 | Martine A. Rothblatt Director, Officer (Chairperson & CEO) | Open-market sale | −2,603 | $470.63 | $1,225,045 |
| Sep 24, 2026 | Martine A. Rothblatt Director, Officer (Chairperson & CEO) | Open-market sale | −2,160 | $471.77 | $1,019,026 |
| Sep 24, 2026 | Martine A. Rothblatt Director, Officer (Chairperson & CEO) | Open-market sale | −580 | $472.73 | $274,184 |
| Sep 24, 2026 | Martine A. Rothblatt Director, Officer (Chairperson & CEO) | Open-market sale | −437 | $474.01 | $207,141 |
| Sep 24, 2026 | Martine A. Rothblatt Director, Officer (Chairperson & CEO) | Open-market sale | −320 | $475.35 | $152,114 |
| Sep 24, 2026 | Martine A. Rothblatt Director, Officer (Chairperson & CEO) | Open-market sale | −280 | $476.51 | $133,424 |
| Sep 24, 2026 | Martine A. Rothblatt Director, Officer (Chairperson & CEO) | Open-market sale | −360 | $477.58 | $171,930 |
| Sep 24, 2026 | Martine A. Rothblatt Director, Officer (Chairperson & CEO) | Open-market sale | −1,480 | $478.61 | $708,337 |
| Sep 24, 2026 | Martine A. Rothblatt Director, Officer (Chairperson & CEO) | Open-market sale | −600 | $479.52 | $287,710 |
| Sep 24, 2026 | Martine A. Rothblatt Director, Officer (Chairperson & CEO) | Open-market sale | −40 | $480.33 | $19,213 |
| Sep 23, 2026 | Martine A. Rothblatt Director, Officer (Chairperson & CEO) | Option exercise | +9,500 | $117.76 | $1,118,720 |
| Sep 23, 2026 | Martine A. Rothblatt Director, Officer (Chairperson & CEO) | Open-market sale | −2,388 | $488.70 | $1,167,007 |
| Sep 23, 2026 | Martine A. Rothblatt Director, Officer (Chairperson & CEO) | Open-market sale | −2,162 | $489.52 | $1,058,351 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.